Research Topics
| Antonella d'Arminio-MonforteSummaryAffiliation: University of Milan Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysisEnrico Girardi
Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L, Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy
BMC Health Serv Res 12:38. 2012..Identification of the determinants of access to investigational drugs is important to promote equity and scientific validity in clinical research. We aimed to analyze factors associated with the use of experimental antiretrovirals in Italy...- Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTICarlo Torti
University of Brescia, Italy
BMC Infect Dis 11:23. 2011..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce... 
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcomeAntonella d'Arminio Monforte
Clinic of Infectious and Tropical Diseases, Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Milan, Italy
Antivir Ther 16:1103-12. 2011..To study the prevalence, predictors and outcome of late HIV diagnosis in the Icona cohort, according to the new European consensus definition of late diagnosis...- Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosisAntonella d'Arminio Monforte
Clinic of Infectious and Tropical Diseases, Dept of Medicine, Surgery and Dentistry, San Paolo Hospital, University of Milan, via A Di Rudinì 8 20142, Milan, Italy
Clin Infect Dis 49:612-22. 2009..We evaluated the correlation between the occurrence of different AIDS-defining illnesses (ADIs) and chronic HCV infection or HCV-related liver cirrhosis in a large Italian cohort of human immunodeficiency virus (HIV)-infected subjects... - HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignanciesAntonella D arminio Monforte
Dipartimento di Medicina, Chirurgia e Odontoiatria, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera Polo Universitario San Paolo, via A Di Rudinì 8 20142 Milano, Italy
AIDS 22:2143-53. 2008..To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency... 
Predictive role of the three-month CD4 cell count in the long-term clinical outcome of the first HAART regimenA d' Arminio Monforte
Institute of Infectious and Tropical Diseases, University of Milan, L Sacco Hospital, Italy
Biomed Pharmacother 55:16-22. 2001..93; 95% Cl: 1.16--7.38). The three-month immunologic response is a reliable predictor of long-term clinical outcome...- Cerebrovascular disease in highly active antiretroviral therapy-treated individuals: incidence and risk factorsAntonella D arminio Monforte
Institute of Infectious Diseases and Tropical Medicine, University of Milan, Milan, Italy
J Neurovirol 11:34-7. 2005..Large-scale epidemiological studies are needed to better define the incidence of cerebrovascular events in HIV-infected patients and the factors associated with their occurrence... - Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive PatientsAntonella d'Arminio Monforte
Istituto di Malattie Infettive e Tropicali, Universita di Milano, Milano, Italy
J Acquir Immune Defic Syndr 38:407-16. 2005.... - Changing incidence of central nervous system diseases in the EuroSIDA cohortAntonella d'Arminio Monforte
Institute of Infectious and Tropical Diseases, University of Milan, I Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
Ann Neurol 55:320-8. 2004.... - Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomesElisabetta Chiesa
Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy
Antivir Ther 8:27-35. 2003..92, P=0.004). CONCLUSIONS: Simplification is safe and effective, but it should be offered to patients with shorter treatment duration, and in good clinical and immunovirological conditions... - Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort studyMarco Bongiovanni
Institute of Infectious and Tropical Diseases, University of Milan, Luigi Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
J Antimicrob Chemother 51:171-4. 2003..Undetectable plasma viraemia was obtained only in patients with < or =5 mutations (61.9%)... - Significant link between sCD30 changes and HIV viremia in patients treated with HAARTPriscilla Biswas
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
J Med Virol 78:1513-9. 2006..The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success... - Cutaneous B-cells non-Hodgkin's lymphoma in a HIV-infected femaleMarco Bongiovanni
Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy
Scand J Infect Dis 37:78-80. 2005 - Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical managementMarco Bongiovanni
Clinic of Infectious and Tropical Diseases, San Paolo Hospital, University of Milan, Italy
Curr HIV Res 5:490-8. 2007..Other studies are mandatory to better elucidate the pathogenesis of NAFLD and the optimal therapeutic strategy for the underlying conditions... - Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavirMarco Bongiovanni
Institute of Infectious Diseases and Tropical Medicine, Luigi Sacco Hospital, University of Milan, Via G B Grassi 74, 20157 Milan, Italy
Int J Antimicrob Agents 22:630-1. 2003..We report here a case of AVN of the bone in a patient taking the new PI lopinavir (LPV)/ritonavir (RTV) as part of a HAART regimen... - Non-invasive markers of liver fibrosis in HCV mono-infected and in HIV/HCV co-infected subjectsMarco Bongiovanni
Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Via di Rudini 8, 20142 Milano, Italy
Med Chem 4:513-19. 2008..More recently, fibrosis scores calculated from statistical models have been described. This review describes the role of non-invasive markers in assessing hepatic fibrosis in both HCV mono-infected and HIV/HCV co-infected subjects... - Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutationsMarco Bongiovanni
Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy
Antivir Ther 8:209-14. 2003..0% and each extra mutation by 14.5%... - Hepatitis B vaccination in HIV-infected subjectsMarco Bongiovanni
Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
Curr Mol Pharmacol 1:191-4. 2008..The immunization of all young and middle-aged adults appears to be the most useful strategy to protect all patient-populations at high risk of sexually transmitted diseases... - Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?Marco Bongiovanni
Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
Clin Infect Dis 45:650-3. 2007.... - Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavirMarco Bongiovanni
Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
AIDS Res Hum Retroviruses 22:1096-105. 2006..The use of LPV/r-based regimens also provided a durable immunologic recovery in highly pretreated HIV-infected subjects... - Tenofovir plus didanosine as Nrti backbone in HIV-infected subjectsMarco Bongiovanni
Clinic of Infectious Diseases, S Paolo Hospital, University of Milan, Via di Rudini 8, 20142 Milan, Italy
Curr Med Chem 13:2789-93. 2006.... - Subclinical hypothyroidism in HIV-infected subjectsMarco Bongiovanni
Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy
J Antimicrob Chemother 58:1086-9. 2006..The correlation between subclinical hypothyroidism [thyroid stimulating hormone (TSH)>4 mIU/L with normal free triiodothyroxine and free thyroxine levels], HIV infection and HAART is still unclear... - Bone diseases associated with human immunodeficiency virus infection: pathogenesis, risk factors and clinical managementMarco Bongiovanni
Clinic of Infectious and Tropical Diseases, Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Italy
Curr Mol Med 6:395-400. 2006..The administration of bisphosphonates (e.g., alendronate), with calcium and vitamin D supplementation, may be a reasonable and effective option to treat osteoporosis in these subjects... - Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effectsMarco Bongiovanni
Institute of Infectious Diseases and Tropical Medicine, Luigi Sacco Hospital, University of Milan, Via G B Grassi 74, 20157 Milano, Italy
Antiviral Res 62:53-6. 2004..40 higher risk of discontinuation in the latter group. In our clinical setting IDV/r showed to be less effective and more toxic than LPV/RTV as first-line HAART... - Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavirMarco Bongiovanni
Institute of Infectious Diseases and Tropical Medicine, Luigi Sacco Hospital, University of Milan, Via G B Grassi 74, 20157 Milan, Italy
AIDS Res Hum Retroviruses 22:132-8. 2006..01 for both), respectively. Patients with high triglyceride and non- HDL cholesterol levels at the start of LPV/r treatment are at higher risk of developing hyperlipidemia... - Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individualsMarco Bongiovanni
Institute of Infectious and Tropical Diseases, Ospedale Luigi Sacco, University of Milan, Via G B Grassi 74, 20157 Milan, Italy
Int J Antimicrob Agents 26:88-91. 2005..Diarrhoea was the most frequent adverse event leading to discontinuation. HCV-HIV co-infected patients and patients with a short exposure to LPV/r have a higher risk of discontinuing LPV/r and should be strictly monitored... - Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAARTMarco Bongiovanni
Institute of Infectious and Tropical Diseases, Ospedale Luigi Sacco, University of Milan, Via G B Grassi 74, 20157 Milano, Italy
J Antimicrob Chemother 55:1003-7. 2005..The long-term virological efficacy of lopinavir/ritonavir-containing highly active antiretroviral therapy (HAART) in HIV-infected patients failing a first-line protease inhibitor (PI)-based regimen is still unclear... - Treatment interruptions in HIV-infected subjectsMarco Bongiovanni
Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Italy
J Antimicrob Chemother 58:502-5. 2006..A clear benefit of STI in patients with chronic infection remains controversial and these benefits are more often observed in patients starting treatment during primary HIV infection... - Potential predictive factors of osteoporosis in HIV-positive subjectsAlfonso Fausto
Department of Radiology, Policlinico San Donato, University of Milan, Via Morandi, 30, 20097 San Donato Milanese, Milan, Italy
Bone 38:893-7. 2006..Traditional risk factors are predictive of osteopenia/osteoporosis also in HIV-subjects; the association with higher HIV-RNA levels can suggest a direct role of HIV itself in the occurrence of bone disease...